New Approach to Decades Old Treatment Yields Increased Survival for Some Prostate Cancer Patients
Rutgers Cancer InstituteResearch coordinated by the ECOG-ACRIN Cancer Research Group and just published in the The New England Journal of Medicine, examines the outcomes of giving the chemotherapy drug docetaxel at the start of androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer. Results showed an increased survival of 13.6 months for patients treated with ADT plus docetaxel than with ADT alone.